1. Home
  2. SPRO vs BZUN Comparison

SPRO vs BZUN Comparison

Compare SPRO & BZUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.58

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Logo Baozun Inc.

BZUN

Baozun Inc.

HOLD

Current Price

$2.52

Market Cap

159.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
BZUN
Founded
2013
2007
Country
United States
China
Employees
N/A
6762
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
159.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
BZUN
Price
$1.58
$2.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
263.4K
Earning Date
05-13-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
$7.89
Revenue Next Year
$300.00
$6.16
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.52
$2.07
52 Week High
$3.08
$4.88

Technical Indicators

Market Signals
Indicator
SPRO
BZUN
Relative Strength Index (RSI) 26.06 35.57
Support Level N/A $2.44
Resistance Level $2.45 $2.58
Average True Range (ATR) 0.14 0.12
MACD -0.05 -0.04
Stochastic Oscillator 8.93 5.21

Price Performance

Historical Comparison
SPRO
BZUN

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About BZUN Baozun Inc.

Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.

Share on Social Networks: